NASDAQ - Horizon Therapeutics Public Limited Company
График котировок Horizon Therapeutics Public Limited Company
Добавить в список сравнения
Добавить в список отслеживания
Добавить в портфель
Основные параметры
Оценка
|
Недооценка
|
Эффективность
|
|||||||||||||||||||||||||||||||||||||
Дивиденды
|
Долг
|
Импульс роста
|
Инсайдерская торговля
Дата сделки | Дата раскрытия | Инсайдер | Тип | Цена | Объем | Количество | Доля до, % | Доля после, % | Документ |
---|---|---|---|---|---|---|---|---|---|
05.11.2020 | 06.11.2020 | Kent Jeff See remarks |
Продажа | 78.94 | 3 784 700.00 | 47944 | 0 | -0.03 | ссылка |
06.11.2020 | 06.11.2020 | Camardo Daniel A. EVP and President, U.S. |
Продажа | 76.76 | 268 660.00 | 3500 | 0 | 0 | ссылка |
05.11.2020 | 06.11.2020 | MOZE BARRY EVP, Chief Admin. Officer |
Продажа | 78.93 | 6 117 080.00 | 77500 | 0 | -0.04 | ссылка |
Основные владельцы
Institutions | Объем | Доля, % |
---|---|---|
Sabrient Systems | 94877 | 0.04 |
Hennion & Walsh, Inc | 400 | 0 |
Principal Global Investors, LLC | 1136526 | 0.51 |
Janus Capital Management LLC | 13982253 | 6.34 |
Allianz Global Investors GmbH | 1264092 | 0.57 |
Fidelity Management & Research Company LLC | 21277027 | 9.64 |
Bellevue Asset Management AG | 321600 | 0.15 |
Paulson & Company Inc | 6691439 | 3.03 |
Allianz Global Investors U.S. LLC | 1478161 | 0.67 |
Pacific Life Fund Advisors LLC (PLFA) | 645777 | 0.29 |
TreeTop Asset Management SA | 177590 | 0.08 |
BlackRock Fund Advisors | 10775170 | 4.88 |
Invesco Advisers, Inc. | 1928813 | 0.87 |
Allianz Global Investors | 403068 | 0.18 |
Eversept Partners, LLC | 607757 | 0.28 |
Voya Investments, LLC | 2402727 | 1.09 |
Liontrust Investment Management Limited | 257242 | 0.12 |
International Biotechnology Trust PLC | 389000 | 0.18 |
FIL Fund Management Limited | 246330 | 0.11 |
Kopp Family Office, LLC | 427465 | 0.19 |
Hennion & Walsh, Inc | 400 | 0 |
Fidelity Management & Research Company LLC | 16620054 | 7.53 |
Paulson & Company Inc | 6691439 | 3.03 |
Invesco Capital Management LLC | 961963 | 0.44 |
Boston Company Asset Mgmt, LLC | 204885 | 0.09 |
Financial Trust Asset Management | 1058 | 0 |
AMG Funds LLC | 152694 | 0.07 |
Security Investors, LLC | 166461 | 0.08 |
Содержится в ETF
ETF | Доля, % | Доходность за год, % | Дивиденды, % |
---|---|---|---|
Vanguard Small Cap ETF | 0.32 | 41.94 | 1.02 |
Vanguard Small Cap Growth ETF | 0.69 | 43.33 | 0.41 |
iShares Nasdaq Biotechnology ETF | 1.64 | 31.26 | 0.19 |
iShares U.S. Pharmaceuticals ETF | 5.78 | 21.89 | 1.20 |
SPDR S&P Pharmaceuticals ETF | 4.92 | 26.40 | 0.46 |
Principal Healthcare Innovators Index ETF | 2.44 | 61.80 | 0.34 |
First Trust Nasdaq Pharmaceuticals ETF | 4.6 | 19.58 | 0.80 |
SoFi Next 500 ETF | 0.99 | 39.16 | 1.07 |
Direxion Daily Pharmaceutical & Medical Bull 3X Shares | 5 | 37.25 | 0.98 |
American Century Mid Cap Growth Impact | 3.6 | 0.45 | |
JPMorgan BetaBuilders U.S. Mid Cap Equity ETF | 0.6 | 0.64 | |
ProShares Ultra Nasdaq Biotechnology | 1.39 | 49.35 | 0.95 |
iShares Russell 2500 ETF | 0.29 | 45.15 | 1.20 |
iShares Edge MSCI Multifactor USA Mid-Cap ETF | 1.58 | 32.25 | 1.16 |
First Trust Health Care AlphaDEX Fund | 2 | 31.84 | 0.61 |
Invesco Dynamic Pharmaceuticals ETF | 3.5 | 29.30 | 0.70 |
Goldman Sachs Hedge Industry VIP ETF | 2.27 | 55.09 | 0.12 |
Invesco Russell 1000 Low Beta Equal Weight ETF | 0.34 | 11.09 | 2.39 |
Похожие компании
Описание Horizon Therapeutics Public Limited Company
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing of medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of rheumatoid arthritis (RA), polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and ankylosing spondylitis to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.